Comparative Pharmacology
Head-to-head clinical analysis: DEXACEN 4 versus ORTIKOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXACEN 4 versus ORTIKOS.
DEXACEN-4 vs ORTIKOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to increased transcription of anti-inflammatory proteins and suppression of pro-inflammatory mediators.
ORTIKOS (acalabrutinib) is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). It forms a covalent bond with the active site cysteine residue (Cys481) in BTK, blocking downstream B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
Dexamethasone 4 mg orally or intravenously every 6-8 hours; typical adult dose is 4-20 mg/day in divided doses, depending on condition.
2 mg orally three times daily (total daily dose 6 mg).
None Documented
None Documented
3-4 hours; prolonged to 6-8 hours in renal impairment (CrCl <30 mL/min)
Terminal half-life of 8 hours (range 6-10) in healthy adults; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 65-80% as unchanged drug; Biliary: 10-15% as metabolites; Fecal: <5%
Renal (70% unchanged), biliary/fecal (30% as metabolites)
Category C
Category C
Corticosteroid
Corticosteroid